BHLHE22 Expression as a Potential Diagnostic and Prognostic Biomarker in Cervical Cancer

Rachmadina Rachmadina; Darmawi Darmawi; Rahmat A Kemal; Ina F Rangkuti; Siti Nurkasanah; Maya Savira

doi:10.5937/scriptamed56-56934

Rachmadina Rachmadina Faculty of Medicine, Universitas Riau
Darmawi Darmawi Department of Histology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia https://orcid.org/0000-0001-5018-2381
Rahmat A Kemal Department of Medical Biology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia https://orcid.org/0000-0002-1630-9526
Ina F Rangkuti Department of Pathological Anatomy, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia https://orcid.org/0009-0009-3778-9512
Siti Nurkasanah Department of Histology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia https://orcid.org/0000-0003-0361-0704
Maya Savira Department of Microbiology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia https://orcid.org/0000-0003-4663-030X

DOI: https://doi.org/10.5937/scriptamed56-56934

Sažetak

Background/Aim: Cervical cancer is a prevalent and deadly form of gynaecological malignancy, particularly among developing countries. BHLHE22 is a transcription factor that functions as a transcriptional inhibitor and is significant in cancer-related regulatory mechanisms. In cervical cancer, epigenetic alterations transpire, notably in the BHLHE22 gene, which influences gene and protein expression. The objective of this research was to examine the protein and gene expression of BHLHE22 in tissue from cervix cancer in comparison to those found in normal cervix, to investigate its association with various clinical profiles and prognoses and to assess the association of BHLHE22 gene expression with tumour-infiltrating immune cells.

Methods: This research employed a cross-sectional analytical study and retrospective cohort analyses. The expression of BHLHE22 protein in tissue from cervix cancer and normal cervix was analysed using immunohistochemistry (IHC) examinations. The level of BHLHE22 gene expression, clinical profiles and prognosis were collected from the GTEx and TCGA studies. The association of BHLHE22 expression and tumour-infiltrating immune cells has been investigated using the Pearson correlation test or Spearman’s rank correlation test from the TIMER database.

Results: BHLHE22 protein and mRNA expression in cervical cancer decreased considerably compared to the normal cervix, with protein expression reduced by 1.5-fold and mRNA expression reduced by 3.6-fold, respectively. High levels of BHLHE22 expression were determined to be linked with favourable disease-specific survival. Furthermore, BHLHE22 expression positively correlated with tumour-infiltrating immune cells with antitumour immunity.

Conclusion: BHLHE22 expression as a biomarker for early detection a prognostic biomarker for disease-specific survival and a modulator of the immune microenvironment in cervical cancer might be suggested.

Reference

Ferlay J, Ervik M, Lavarsanne M, Colombet M, Mery L, Pineros M, et al. Global Cancer Observatory: Cancer Today [Internet]. 2024 [Cited: 1-Mar-2024]. Available from: https://gco.iarc.who.int/today

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May;74(3):229–63. doi: 10.3322/caac.21834.

Holcakova J, Bartosik M, Anton M, Minar L, Hausnerova J, Bednarikova M, et al. New trends in the detection of gynecological precancerous lesions and early-stage cancers. Cancers (Basel). 2021 Dec 1;13(24):6339. doi: 10.3390/cancers1324633.

Tabatabaei FS, Saeedian A, Azimi A, Kolahdouzan K, Esmati E, Safaei AM. Evaluation of survival rate and associated factors in patients with cervical cancer: a retrospective cohort study. J Res Health Sci. 2022 Mar 1;22(2):e00552. doi: 10.34172/jrhs.2022.87.

Shiraz A, Crawford R, Egawa N, Griffin H, Doorbar J. The early detection of cervical cancer. The current and changing landscape of cervical disease detection. Cytopathology. 2020 Jul 1;31(4):258–70. doi: 10.1111/cyt.12835.

Zhang L, Tan W, Yang H, Zhang S, Dai Y. Detection of host cell gene/HPV DNA methylation markers: a promising triage approach for cervical cancer. Front Oncol. 2022 Mar 25;12:831949. doi: 10.3389/fonc.2022.831949.

George IA, Chauhan R, Dhawale RE, Iyer R, Limaye S, Sankaranarayanan R, et al. Insights into therapy resistance in cervical cancer. Vol. 6, Advances in Cancer Biology - Metastasis. Elsevier Inc.; 2022. doi: 10.1016/j.adcanc.2022.100074.

Inoue F, Sone K, Toyohara Y, Takahashi Y, Kukita A, Hara A, et al. Targeting epigenetic regulators for endometrial cancer therapy: Its molecular biology and potential clinical applications. Int J Mol Sci. 2021 Mar 1;22(5):1–18. doi: 10.3390/ijms22052305.

Darmawi, Chen LY, Su PH, Liew PL, Wang HC, Weng YC, et al. BHLHE22 expression is associated with a proinflammatory immune microenvironment and confers a favorable prognosis in endometrial cancer. Int J Mol Sci. 2022 Jul 1;23(13):8. doi: 10.3390/ijms23137158.

Costa AC, Santos JMO, Gil da Costa RM, Medeiros R. Impact of immune cells on the hallmarks of cancer: A literature review. Crit Rev Oncol Hematol. 2021 Dec;168:103541. doi: 10.1016/j.critrevonc.2021.103541.

Dakal TC, George N, Xu C, Suravajhala P, Kumar A. Predictive and prognostic relevance of tumor-infiltrating immune cells: tailoring personalized treatments against different cancer types. Cancers (Basel). 2024 Apr 23;16(9):1626. doi: 10.3390/cancers16091626.

Huang RL, Su PH, Liao YP, Wu TI, Hsu YT, Lin WY, et al. Integrated epigenomics analysis reveals a DNA methylation panel for endometrial cancer detection using cervical scrapings. Clin Cancer Res. 2017 Jan 1;23(1):263–72. doi: 10.1158/1078-0432.CCR-16-0863.

Liew PL, Huang RL, Wu TI, Liao CC, Chen CW, Su PH, et al. Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings. Clin Epigenetics. 2019 Nov 28;11(1):170. doi: 10.1186/s13148-019-0765-3.

Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020 Jun 1;38(6):675–8. doi: 10.1038/s41587-020-0546-8.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020 Jul 2;48(W1):W509–14. doi: 10.1093/nar/gkaa407.

Xu ZP, Dutra A, Stellrecht CM, Wu C, Piatigorsky J, Saunders GF. Functional and structural characterization of the human gene BHLHB5, encoding a basic helix-loop-helix transcription factor. Genomics. 2002;80(3):311–8. doi: 10.1006/geno.2002.6833.

Bowden SJ, Doulgeraki T, Bouras E, Markozannes G, Athanasiou A, Grout-Smith H, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023 Dec 1;21(1):274. doi: 10.1186/s12916-023-02965-w.

Kakotkin V V., Semina E V., Zadorkina TG, Agapov MA. Prevention strategies and early diagnosis of cervical cancer: current state and prospects. Diagnostics. 2023 Feb 1;13(4):610. doi: 10.3390/diagnostics13040610.

Yin C, Wang M, Wang Y, Lin Q, Lin K, Du H, et al. BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer. J Immunother Cancer. 2023 Mar 1;11(3):e005532. doi: 10.1136/jitc-2022-005532.

Zhu J, Cao L, Wen H, Bi R, Wu X, Ke G. The clinical and prognostic implication of deep stromal invasion in cervical cancer patients undergoing radical hysterectomy. J Cancer. 2020;11(24):7368–77. doi: 10.7150/jca.50752.

Santoro A, Inzani F, Angelico G, Arciuolo D, Bragantini E, Travaglino A, et al. Recent advances in cervical cancer management: a review on novel prognostic factors in primary and recurrent tumors. Cancers (Basel). 2023 Feb 1;15(4):1137. doi: 10.3390/cancers15041137.

Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. NEJM. 2018 Nov 15;379(20):1895–904. doi: 10.1056/NEJMoa1806395.

Litwin TR, Irvin SR, Chornock RL, Sahasrabuddhe V V., Stanley M, Wentzensen N. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. Br J Cancer. 2021 Feb 16;124(4):831–41. doi: 10.1038/s41416-020-01184-x.

Wild CM, Garrido F, Dannecker C, Köpke MB, Chateau MC, Boissière-Michot F, et al. Prognostic relevance of tumor-infiltrating immune cells in cervix squamous cell carcinoma. Cancers (Basel). 2023 Oct 1;15(20):4952. doi: 10.3390/cancers15204952.

Ferrall L, Lin KY, Roden RBS, Hung CF, Wu TC. Cervical cancer immunotherapy: Facts and hopes. Clinical Cancer Research. 2021 Sep 15;27(18):4953–73. doi: 10.1158/1078-0432.CCR-20-2833.

Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021 Feb 1;52. doi: 10.1016/j.smim.2021.101481.

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017 Jul 1;14(7):399–416. doi: 10.1038/nrclinonc.2016.217.

Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021 Jul 1;22(13):6995. doi: 10.3390/ijms22136995.